Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Divi's Laboratories Ltd

DIVISLAB.NS ✓ COMPLIANTFree checks used up today ☆ Track — members

NSE · Healthcare · Pharmaceuticals ·

India Large Cap Analyst: HOLD

Last Close

$96.63

▼ -0.30%

Market Cap $25.75B · Vol 1.04M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

83.14

FWD: 66.39

Market Cap

$25.75B

Large Cap

Div Yield

0.33%

Annual dividend

EPS Growth

+23.41%

YoY

RSI (14)

45.78

Momentum

Beta

0.77

vs Market

52W High

$102.72

4.15% below

52W Low

$59.56

60.13% above

Volume

1.04M

Avg 547.94K

P/B

9.42

Price-to-book

ROE

16.65%

Return on equity

Free Float

48.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Divi's Laboratories Ltd (DIVISLAB.NS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DIVISLAB.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.54%

-2.03%

+24.04%

+45.76%

YTD

+43.32%

+39.09%

+129.28%

+80.59%

Financials & Valuation

TTM · Annual

Total Revenue	$1.13B
Net Income	$274.78M
Revenue Growth (YoY)	+27.80%
Gross Margin	50.08%
Operating Margin	28.20%
Net Profit Margin	24.32%
ROE	16.65%
ROA · ROIC	18.33% · 16.29%

P/E Ratio	83.14
Forward P/E (FY1)	66.39
PEG Ratio	3.57
P/S	14.95
P/B	9.42
P/FCF	317.65
EPS Growth	+23.41%
Outstanding Shares	265.47M

Technical Indicators

50-Day SMA	$96.48
200-Day SMA	$76.18
RSI (14)	45.78
Beta	0.77
52-Week High	$102.72
52-Week Low	$59.56

Volume Today	1.04M
Avg Daily Volume (30D)	547.94K
Relative Volume	1.90x
Volatility (10D)	21.44
Volatility (30D)	23.13
Free Float	48.00%

Analyst Consensus

HOLD

Current Price $96.63

Mean Target $87.91

52W Low$59.56 52W High$102.72

Current

Target

$59.56 $102.72

Current Analyst target

-9.02% downside risk · 26 analysts

Identifiers

ExchangeNSE

FIGIBBG001SJGYK1

ISININE361B01024

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +2.83% JNJ Johnson & Johnson +3.81% ABBV AbbVie Inc. +0.14% NVS Novartis AG +1.52% NOVN.S Novartis AG +1.58%

Company Profile

Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company's products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Quetiapine Fumarate, Naproxen Sodium, Olmesartan, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, and others. In addition to generics, the Company, through its custom synthesis, supports innovator pharma companies. It is engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company's subsidiaries include Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.